O-RAY PHARMA
Medtech · Private
Sustained-release fluticasone pellets (OR-102) implanted in the cochlea for treating autoimmune inner ear disease
oraypharma.com →- Grants
- $4.3M
- 9 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 5
- 1 granted · 4 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20142016201820202022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Sustained Release Inner Ear Delivery of Corticosteroid | $498,847 | |
| Federal grant | Department of Health and Human Services · Phase I · Intratympanic delivery of biologics for treatment of autoimmune inner ear disease | $161,422 | |
| Federal grant | Department of Health and Human Services · Phase II · Prevention of Children's Tympanostomy Tube Otorrhea | $634,501 | |
| Federal grant | Department of Health and Human Services · Phase II · Prevention of Children's Tympanostomy Tube Otorrhea | $567,267 | |
| Federal grant | Department of Health and Human Services · Phase I · Inner ear therapeutics for sustained treatment of autoimmune inner ear disease | $169,214 | |
| Federal grant | Department of Health and Human Services · Phase I · Inner ear therapeutics for sustained treatment of autoimmune inner ear disease | $169,214 | |
| Federal grant | Department of Health and Human Services · Phase II · Prevention of Children's Tympanostomy Tube Otorrhea | $284,456 | |
| Federal grant | Department of Health and Human Services · Phase II · IND-enabling Preclinical Development of Sustained Release Inner Ear Delivery of Corticosteroid | $886,552 | |
| Federal grant | Department of Health and Human Services · Phase II · IND-enabling Preclinical Development of Sustained Release Inner Ear Delivery of Corticosteroid | $879,062 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2018 | TET MEDICAL | — | — |
| 2019 | NEURALENZ, INC | — | — |
| 2020 | PRECYTE INC | — | — |
| 2021 | O-RAY PHARMA | — | — |
| 2022 | ANOVA BIOMEDICAL, INC. | — | — |
| 2023 | Lapovations, LLC | — | — |
| 2024 | Dura LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Solid Drug Implants For Intracochlear Delivery Of Therapeutics For The Treatment Of Otic Disordersgranted
- Process For Manufacturing Drug Delivery Formulationsapplication
- Solid Drug Implants For Intracochlear Delivery Of Therapeutics For The Treatment Of Otic Disordersapplication
- Process For Manufacturing Drug Delivery Formulationsapplication
- Solid Drug Implants For Intracochlear Delivery Of Therapeutics For The Treatment Of Otic Disordersapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.